Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Ahead of 1Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Fate Therapeutics (FATE) Announces Pact with Janssen (JNJ) for Novel iPSC-derived Cell-based Cancer Immunotherapies
April 2, 2020 4:54 PM EDTFate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets. The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product... More
Johnson & Johnson (JNJ) PT Lowered to $150 at Wells Fargo
April 2, 2020 6:43 AM EDTWells Fargo analyst Larry Biegelsen lowered the price target on Johnson & Johnson (NYSE: JNJ) to $150.00 (from $165.00) while maintaining a Overweight rating.... More
